CalciMedica (CALC) Competitors $2.35 -0.09 (-3.69%) Closing price 02/21/2025 03:58 PM EasternExtended Trading$2.33 -0.02 (-1.06%) As of 02/21/2025 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends CALC vs. BMEA, BDTX, CABA, TSVT, KYTX, SGMT, IVA, RENB, TELO, and CRBUShould you be buying CalciMedica stock or one of its competitors? The main competitors of CalciMedica include Biomea Fusion (BMEA), Black Diamond Therapeutics (BDTX), Cabaletta Bio (CABA), 2seventy bio (TSVT), Kyverna Therapeutics (KYTX), Sagimet Biosciences (SGMT), Inventiva (IVA), Renovaro (RENB), Telomir Pharmaceuticals (TELO), and Caribou Biosciences (CRBU). These companies are all part of the "pharmaceutical products" industry. CalciMedica vs. Biomea Fusion Black Diamond Therapeutics Cabaletta Bio 2seventy bio Kyverna Therapeutics Sagimet Biosciences Inventiva Renovaro Telomir Pharmaceuticals Caribou Biosciences Biomea Fusion (NASDAQ:BMEA) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, community ranking, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations. Which has better earnings & valuation, BMEA or CALC? CalciMedica is trading at a lower price-to-earnings ratio than Biomea Fusion, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomea FusionN/AN/A-$117.25M-$4.01-0.86CalciMedicaN/AN/A-$34.36M-$1.08-2.18 Do analysts recommend BMEA or CALC? Biomea Fusion currently has a consensus target price of $39.36, indicating a potential upside of 1,037.68%. CalciMedica has a consensus target price of $18.00, indicating a potential upside of 665.96%. Given Biomea Fusion's higher probable upside, equities research analysts clearly believe Biomea Fusion is more favorable than CalciMedica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomea Fusion 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00CalciMedica 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is BMEA or CALC more profitable? Biomea Fusion's return on equity of -118.90% beat CalciMedica's return on equity.Company Net Margins Return on Equity Return on Assets Biomea FusionN/A -118.90% -93.66% CalciMedica N/A -164.24%-103.53% Does the MarketBeat Community prefer BMEA or CALC? Biomea Fusion received 43 more outperform votes than CalciMedica when rated by MarketBeat users. However, 93.75% of users gave CalciMedica an outperform vote while only 69.05% of users gave Biomea Fusion an outperform vote. CompanyUnderperformOutperformBiomea FusionOutperform Votes5869.05% Underperform Votes2630.95% CalciMedicaOutperform Votes1593.75% Underperform Votes16.25% Does the media refer more to BMEA or CALC? In the previous week, Biomea Fusion and Biomea Fusion both had 1 articles in the media. Biomea Fusion's average media sentiment score of 1.93 beat CalciMedica's score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomea Fusion 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive CalciMedica 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, BMEA or CALC? Biomea Fusion has a beta of -0.34, suggesting that its share price is 134% less volatile than the S&P 500. Comparatively, CalciMedica has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Do insiders & institutionals have more ownership in BMEA or CALC? 96.7% of Biomea Fusion shares are held by institutional investors. 27.6% of Biomea Fusion shares are held by insiders. Comparatively, 41.6% of CalciMedica shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. SummaryBiomea Fusion beats CalciMedica on 9 of the 14 factors compared between the two stocks. Get CalciMedica News Delivered to You Automatically Sign up to receive the latest news and ratings for CALC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALC vs. The Competition Export to ExcelMetricCalciMedicaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.90M$7.06B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-2.185.8226.1519.13Price / SalesN/A268.05435.3370.72Price / CashN/A65.6738.0134.83Price / Book1.656.717.644.62Net Income-$34.36M$138.55M$3.19B$245.94M7 Day Performance-6.37%-2.63%-2.11%-2.62%1 Month Performance-20.07%-2.33%-0.49%-2.15%1 Year Performance-46.71%-5.33%16.44%12.95% CalciMedica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALCCalciMedica2.5967 of 5 stars$2.35-3.7%$18.00+666.0%-47.7%$32.90MN/A-2.1830Gap DownBMEABiomea Fusion3.3309 of 5 stars$3.73+3.3%$39.36+955.3%-77.4%$135.17MN/A-0.9350Positive NewsBDTXBlack Diamond Therapeutics3.3793 of 5 stars$2.37+1.3%$15.50+554.0%-53.7%$134.10MN/A-1.7890Short Interest ↓Positive NewsCABACabaletta Bio2.2549 of 5 stars$2.71+0.4%$22.71+738.2%-90.7%$132.47MN/A-1.2650Analyst ForecastTSVT2seventy bio2.1861 of 5 stars$2.54-0.4%$7.20+183.5%-53.2%$131.03M$45.62M-1.37440Analyst ForecastNews CoveragePositive NewsKYTXKyverna Therapeutics1.1513 of 5 stars$3.03-0.3%$25.71+748.7%-89.9%$130.81M$7.03M0.0096SGMTSagimet Biosciences1.7999 of 5 stars$4.25-3.4%$23.00+441.2%-38.9%$130.35M$2M0.008IVAInventiva1.9923 of 5 stars$2.47-0.4%$13.25+436.4%-13.1%$129.63M$18.91M0.00100Analyst ForecastNews CoverageRENBRenovaro0.7629 of 5 stars$0.81+9.0%N/A-61.1%$128.39MN/A-0.8420Earnings ReportNews CoverageGap UpTELOTelomir Pharmaceuticals2.2879 of 5 stars$4.29+0.5%N/A-54.8%$127.67MN/A-7.401Analyst ForecastNews CoverageCRBUCaribou Biosciences3.1326 of 5 stars$1.35+3.1%$10.33+665.4%-80.8%$122.25M$11.48M-0.82100 Related Companies and Tools Related Companies Biomea Fusion Alternatives Black Diamond Therapeutics Alternatives Cabaletta Bio Alternatives 2seventy bio Alternatives Kyverna Therapeutics Alternatives Sagimet Biosciences Alternatives Inventiva Alternatives Renovaro Alternatives Telomir Pharmaceuticals Alternatives Caribou Biosciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CALC) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CalciMedica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CalciMedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
